Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis

The Pharmacogenomics Journal
M VerbelenC M Lewis

Abstract

Clozapine is the only evidence-based therapy for treatment-resistant schizophrenia, but it induces agranulocytosis, a rare but potentially fatal haematological adverse reaction, in less than 1% of users. To improve safety, the drug is subject to mandatory haematological monitoring throughout the course of treatment, which is burdensome for the patient and one of the main reasons clozapine is underused. Therefore, a pharmacogenetic test is clinically useful if it identifies a group of patients for whom the agranulocytosis risk is low enough to alleviate monitoring requirements. Assuming a genotypic marker stratifies patients into a high-risk and a low-risk group, we explore the relationship between test sensitivity, group size and agranulocytosis risk. High sensitivity minimizes the agranulocytosis risk in the low-risk group and is essential for clinical utility, in particular in combination with a small high-risk group.

References

Mar 11, 1977·European Journal of Clinical Pharmacology·J Idänpään-HeikkiläI P Palva
Jan 1, 1992·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S L Gerson, H Meltzer
Jul 15, 1993·The New England Journal of Medicine·J M AlvirJ A Schaaf
Oct 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·K AtkinD O'Sullivan
Jan 1, 1997·Current Medical Research and Opinion·H Y Meltzer
May 2, 2000·The British Journal of Psychiatry : the Journal of Mental Science·J MunroR Kerwin
Jan 7, 2003·Archives of General Psychiatry·Herbert Y MeltzerUNKNOWN International Suicide Prevention Trial Study Group
Dec 22, 2007·Human Psychopharmacology·Robert J Flanagan, Louisa Dunk
Feb 8, 2008·The New England Journal of Medicine·Simon MallalUNKNOWN PREDICT-1 Study Team
Aug 7, 2008·Pharmacogenomics·Carolin Opgen-Rhein, Michael Dettling
Apr 28, 2010·Journal of Psychiatry & Neuroscience : JPN·Ridha Joober, Patricia Boksa
Sep 28, 2010·The Journal of Clinical Psychiatry·Maria C AthanasiouCarol R Reed
Feb 22, 2011·Current Psychiatry Reports·Nabilah I ChowdhuryJames L Kennedy
Nov 8, 2011·Irish Journal of Medical Science·J P A M BogersB Bakker
Apr 7, 2012·The Journal of Clinical Psychiatry·Liisa Lahdelma, Björn Appelberg
Sep 26, 2012·Clinical Schizophrenia & Related Psychoses·Herbert Y Meltzer
Nov 13, 2012·The Journal of Clinical Psychiatry·Dan CohenPeter F J Schulte
Oct 8, 2013·Schizophrenia Research·Johan ReutforsUrban Osby
Nov 19, 2013·Pharmacogenomics·Benjamin W J SpencerUNKNOWN CRESTAR Consortium
Apr 9, 2014·BMC Psychiatry·Stephanie Warnez, Silvia Alessi-Severini
May 27, 2014·Frontiers in Genetics·Berta AlmogueraHakon Hakonarson
Sep 5, 2014·Nature Communications·Jacqueline I GoldsteinPatrick F Sullivan

❮ Previous
Next ❯

Citations

May 22, 2016·Expert Opinion on Drug Safety·G RemingtonV Powell
Apr 19, 2017·The Pharmacogenomics Journal·S A J de WithR A Ophoff
Jul 10, 2018·Current Opinion in Psychiatry·Kevin J LiLynn E DeLisi
Feb 16, 2019·Pharmacogenomics·Sophie E Legge, James Tr Walters
Jul 6, 2019·Tropical Animal Health and Production·Lan MuBizhi Huang
Nov 26, 2020·Therapeutic Drug Monitoring·Smita PattanaikJasmina Ahluwalia
Dec 23, 2021·Toxicological Sciences : an Official Journal of the Society of Toxicology·Samantha Christine SernoskieJack Uetrecht

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The Journal of Neuropsychiatry and Clinical Neurosciences
Marc Ziegenbein, Iris T Calliess
The Australian and New Zealand Journal of Psychiatry
S Fenner, R Date
© 2022 Meta ULC. All rights reserved